Ca2+ channels in the apical membrane of the toad urinary bladder.

Van Driessche W

Pflugers Archiv : European journal of physiology1 Oct 1987Cited by 16 (Europe PMC)

PMID2446254DOI10.1007/bf00580272PepBankPUB-02446254

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueMechanism
In the toad urinary bladder, oxytocin treatment enhanced the Lorentzian component of the current fluctuation power density spectrum.
In plain wordsIn toad bladder tissue in the lab, oxytocin increased a noise signal that reflects ion channel activity.
Peptide
Oxytocin
Outcome
IncreaseLorentzian component of current fluctuation
Study
toadn: not reported in source
toad urinary bladder
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The power density spectrum of the fluctuation in current contained a Lorentzian component which was enhanced by oxytocin treatment.
Report a problemFND-0244625401
02LabEx vivo tissueMechanism
In the toad urinary bladder with Ca2+, Ba2+ or Mg2+ as principal mucosal cation, the La3+-sensitive current component stayed negligible, also during oxytocin treatment.
In plain wordsIn toad bladder tissue in the lab, oxytocin did not produce this current when calcium, barium or magnesium carried it.
Peptide
Oxytocin
Outcome
No significant changeLa3+-sensitive current with Ca2+, Ba2+ or Mg2+ as mucosal cation
Study
toadn: not reported in source
toad urinary bladder
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
In experiments with Ca2+, Ba2+ or Mg2+ as principal mucosal cation, the La3+-sensitive Isc component was negligible under control conditions and during oxytocin treatment.
Report a problemFND-0244625402

Studies that did not test the peptide alone2

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

03LabNot a test of Oxytocin aloneEx vivo tissueMechanism
In the toad urinary bladder, adding 50 nmol/l Ag+ during oxytocin treatment caused an additional large increase of the La3+-sensitive current component.
In plain wordsIn toad bladder tissue in the lab, silver ions added a further large rise in this current during oxytocin treatment.
Peptide
Oxytocin
Outcome
IncreaseLa3+-sensitive current increase from mucosal Ag+ during oxytocin treatment
Study
toadn: not reported in source
toad urinary bladder
Outcome group
Receptor activity and mechanism · Kidney and urinary
Source sentences
Summary
The present study demonstrates that the addition of 50 nmol/l Ag+ to the mucosal medium during oxytocin treatment caused an additional large increase of the La3+-sensitive Isc component.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0244625403
04LabNot a test of Oxytocin aloneEx vivo tissueMechanism
In the toad urinary bladder, administration of mucosal Ag+ made the oxytocin-enhanced Lorentzian component disappear.
In plain wordsIn toad bladder tissue in the lab, silver ions removed the noise signal that oxytocin had increased.
Peptide
Oxytocin
Outcome
DecreaseLorentzian component after mucosal Ag+
Study
toadn: not reported in source
toad urinary bladder
Outcome group
Receptor activity and mechanism · Kidney and urinary
Source sentences
Summary
The Lorentzian component disappeared as a consequence of the administration of mucosal Ag+.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0244625404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 20:03 UTC
Study results updated
Version 1
9 Oct 2026, 02:52 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.